Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis

  06 January 2021

The proportion of patients infected with SARS-CoV-2 that are prescribed antibiotics is uncertain, and may contribute to patient harm and global antibiotic resistance. Our objective was to estimate the prevalence and associated factors of antibiotic use in patients with confirmed COVID-19.

Three-quarters of patients with COVID-19 receive antibiotics, prescribing is significantly higher than the estimated prevalence of bacterial co-infection. Unnecessary antibiotic use is likely high in patients with COVID-19.

 

Author(s): Bradley J. Langford, PharmD Miranda So, PharmD Sumit Raybardhan, BScPhm MPH Valerie Leung, BScPhm MBA Jean-Paul R. Soucy, MSc Duncan Westwood, BA Nick Daneman, MD, MSc Derek R. MacFadden, MD, ScD
Effective Surveillance   Healthy Animals  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

Register

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed